Business, energy, technology, markets and global industry news from Business News Today

weight loss drugs

PharmaDeviceNews weight loss drugs
Representative image of obesity treatment research. Kalohexis’ 710GO data highlights growing interest in dual MC3R and MC4R activation as the next frontier in weight loss drug development.
Pharma & Biotech

Kalohexis 710GO data puts melanocortin obesity drugs back in the metabolic spotlight

GLP-1 drugs dominate obesity care, but Kalohexis is testing a different pathway. 710GO could shift the next weight loss race.

Read More
Pharma & Biotech

Could Caliway’s CBL-514 become a metabolic add-on to semaglutide and tirzepatide?

GLP-1 drugs drive weight loss, but rebound and body composition gaps remain. Caliway’s CBL-514 may test the next obesity frontier.

Read More
Pharma & Biotech

Can Currax and Peek make oral obesity treatment easier to access for self-funded employers?

Currax expands Contrave access through PeekDirect. Read what this could mean for obesity drug pricing, employers, and non-GLP-1 treatment adoption.

Read More
Novo Nordisk’s higher-dose Wegovy nears EU launch with 20.7% weight loss
Pharma & Biotech

Can Novo Nordisk’s semaglutide 7.2 mg set a new standard in obesity treatment?

Novo Nordisk's semaglutide 7.2 mg achieves 20.7% weight loss. Find out what this EU regulatory step means for obesity treatment and patient outcomes in 2026.

Read More